Pharvaris N.V. (NASDAQ:PHVS) Stock Has Consensus Target Price of $59.87

Posted by George Bondi on Oct 4th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $59.87.

Several analysts have commented on PHVS shares. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price objective on shares of Pharvaris in a research note on Tuesday, September 8th. New Street Research set a $60.00 price objective on Pharvaris in a research report on Friday, August 14th. Guggenheim increased their price target on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners boosted their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Finally, Wedbush increased their target price on shares of Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th.

Get Our Latest Research Report on PHVS

Pharvaris Price Performance

Shares of PHVS stock opened at $31.19 on Tuesday. The firm’s 50-day moving average is $35.05 and its two-hundred day moving average is $32.16. Pharvaris has a 12 month low of $20.65 and a 12 month high of $43.25. The company has a market capitalization of $2.04 billion, a PE ratio of -10.23 and a beta of -2.46.

Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Sell-side analysts forecast that Pharvaris will post -3.12 EPS for the current year.

Insider Buying and Selling

In other news, Director Elisabeth Bjork sold 52,500 shares of Pharvaris stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the transaction, the director owned 15,167 shares in the company, valued at approximately $574,677.63. This trade represents a 77.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David W. Nassif sold 6,000 shares of Pharvaris stock in a transaction on Monday, September 21st. The shares were sold at an average price of $36.47, for a total value of $218,820.00. Following the sale, the chief financial officer directly owned 114,300 shares of the company’s stock, valued at $4,168,521. This represents a 4.99% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 513,102 shares of company stock worth $18,643,666. 11.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pharvaris

Large investors have recently made changes to their positions in the business. venBio Partners LLC purchased a new position in Pharvaris during the second quarter valued at approximately $160,569,809. Wellington Management Group LLP boosted its holdings in Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after buying an additional 274,034 shares in the last quarter. Commodore Capital LP boosted its holdings in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP raised its position in shares of Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the period.

About Pharvaris

(Get Free Report)

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.